Fabrication of supramolecular nano-assembly irinotecan prodrug into polymeric nanomaterials for delivery in cervical carcinoma therapy

Abstract

GLOBOCAN estimates in 2020 on the basis of occurrence, mortality, and development for 36 distinct types of tumor cells worldwide. Chemotherapy is the most preferred treatment for carcinoma, and also for hormonal, radiation, autoimmune, and genetic disorders. We propose a straightforward and cost-effective way to overcome the myriad barriers to the therapeutic potential of irinotecan (SN-38), including the rebuilding of medicines, targeting of supramolecular nanoassemblies, and therapeutic treatments. The drug SN-38 was capable by covalent combination of lipophilic linoleic acid by the end of carboxyl group action to provide an impulsive nanoassembly to extremely stable nanomaterials (NMs). The morphology of the recently synthesized SN-38-NM was tested by electron microscopy. The anticarcinoma properties of both HeLa and CaSki (cervical carcinoma lines) of SN-38 and SN-38-NMs were evaluated after successful synthesis. Further research on mechanistic cell death pathways showed that proliferation of cervical carcinoma cell lines was correlated with cells subjected to apoptosis, including AO/EB staining, nuclear staining, and flow cytometric studies. SN-38-NMs have higher biocompatibility in conjunction with free SN-38. This report describes SN-38-NMs as a positive and secure treatment device for cervical carcinoma, which requires further clinical assessment.